Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
During the inflammatory process, hepcidin overexpression favours the development of anaemia of chronic diseases which represents the second most common form of anaemia worldwide. The identification of therapeutic agents decreasing hepcidin expression is therefore an important goal. The aim of this study was to target the STAT3 signalling involved in the development of increased hepcidin expression related to chronic inflammation. In a co-culture model associating mouse hepatocytes and rat liver epithelial cells, the mRNA levels of hepcidin1, albumin, aldolase B, Cyp3a4, Stat3, Smad4 and iron regulatory genes were measured by real-time PCR. STAT3 and phosphorylated SMAD1/5/8 proteins were analysed by Western blot. At variance of hepatocyte pure culture, co-culture provided high levels of hepcidin1 mRNA, reaching 400% of the freshly isolated hepatocyte values after 6 days of culture. Hepcidin expression was associated with the maintenance of hepatocyte phenotype, STAT3 phosphorylation and functional BMP/SMAD pathway. Stat3 siRNAs inhibited the hepcidin1 mRNA expression. STAT3 inhibitors, including curcumin, AG490 and a peptide (PpYLKTK), reduced hepcidin1 mRNA expression even when cells were additionally exposed to IL-6. Hepcidin1 mRNA was expressed at high levels by hepatocytes in the co-culture model, and STAT3 pathway activation was controlled through STAT3 inhibitors. Such inhibitors could be useful to prevent anaemia related to hepcidin overexpression during chronic inflammation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies with cell and mouse models showed that downstream inhibition of the IL-6/STAT3 signaling pathway by using small molecule inhibitors of STAT3 (curcumin, AG490 and PpYLKTK) likewise decreases hepcidin (Jiao et al., 2009; Fatih et al., 2010; Zhang et al., 2011).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Fatih et al., 2010
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin acts by promoting the degradation of ferroportin, a cellular iron exporter expressed on the cell membrane, thus limiting iron egress [ 4 ].”
BackgroundWeiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800 · cited 2×
“Moreover, in pure primary hepatocyte cultures, there is a quick and strong decrease of both differentiated function and hepcidin expression [2, 14 ].”
BackgroundResultMolecular targets of dietary agents for prevention and therapy of cancer
Aggarwal, B. B., & Shishodia, S. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.009 · Cited by 1,754
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 3×
“Hepcidin, a peptide produced mainly by hepatocytes [1, 2 ], is involved in the control of iron metabolism [3].”
BackgroundResultInfluentialSelf-citationHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression
Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T. A., Campagna, J. A., Chung, R. T., Schneyer, A. L., Woolf, C. J., et al. (2006) · Nature Genetics · doi:10.1038/ng1777 · Cited by 1,026 · cited 2×
“Abnormal decrease of BMP/HJV/SMAD signalling, linked to mutation in hemojuvelin gene, induces low hepcidin levels leading to a juvenile form of genetic haemochromatosis [ 5 ].”
BackgroundHereditary Hemochromatosis — A New Look at an Old Disease
Pietrangelo, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031573 · Cited by 992 · cited 1×
“These results contrast with some recent in vitro data [ 27 , 28].”
ResultInterleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
B. Mythri, R., & M. Srinivas Bharath, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212798918995 · Cited by 323
Alcayaga-Miranda, F., Cuenca, J., & Khoury, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00339 · Cited by 296
Hepcidin in Human Iron Disorders: Diagnostic Implications
Kroot, J. J., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2009.140053 · Cited by 246
Metadata
- Authors
- Fatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Détivaud, L., Leroyer, P., Brissot, P., & Loréal, O.
- Affiliations
- Inserm (FR)
- Corresponding author
- Loréal, Olivier
- Venue
- Journal of Molecular Medicine
- Published
- 2010-02-19
- Volume
- 88
- Issue
- 5
- Pages
- 477-486
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2101299013
- Cited by
- 59
- References
- 34
- Citations by year
- 2025: 3 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 2 · 2014: 2 · 2013: 7 · 2012: 3
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- hepcidin, STAT3, STAT3 inhibitor, anemia of chronic disease, chronic inflammation, hepatocytes, curcumin, AG490, interleukin-6, iron regulation, hepatocyte phenotype, co-culture model
- MeSH terms
- Animals, Cells, Cultured, Gene Expression Regulation, Male, Mice, Inbred C57BL, Phosphorylation, Coculture Techniques, Hepatocytes, Antimicrobial Cationic Peptides, STAT3 Transcription Factor, Mice, Rats, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. https://app.cochat.ai/papers/10.1007/s00109-009-0588-3
- The paper
- Fatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Détivaud, L., Leroyer, P., Brissot, P., & Loréal, O. (2010). Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-009-0588-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.